Proven to reduce mouth and throat soreness associated with oral mucositis (OM)1
MuGard® Oral Mucoadhesive forms a protective layer over the oral mucosa, providing soothing relief from painful OM.1,2
MuGard is a 510(k) cleared medical device.
Indication and Important Safety Information
Indication: MuGard® Oral Mucoadhesive is indicated for the management of oral mucositis/stomatitis (that may be caused by radiotherapy and/or chemotherapy) and all types of oral wounds (mouth sores and injuries), including aphthous ulcers/canker sores and traumatic ulcers, such as those caused by oral surgery or ill-fitting dentures or braces.
Contraindications: MuGard is contraindicated in patients with known hypersensitivity to any of the ingredients in the formulation.
Special Precautions for Use: Patients should avoid eating or drinking for at least one hour after using MuGard. After use, patients should replace the bottle cap and tightly seal the bottle. This product should not be used after the expiration date shown on the carton and product label. Do not use this product in patients with known sensitivity to any of the product’s ingredients. Dilution of the product prior to use is not recommended.
Please see full Prescribing Information.
References: 1. Allison RR, Ambrad AA, Arshoun Y, et al. Multi-institutional, randomized, double-blind, placebo-controlled trial to assess the efficacy of a mucoadhesive hydrogel (MuGard) in mitigating oral mucositis symptoms in patients being treated with chemoradiation therapy for cancers of the head and neck. Cancer. 2014;120(9):1433-1440. 2. MuGard [package insert]. Dallas, TX: PlasmaTech Biopharmaceuticals, Inc; 2014. 3. Peterson DE, Bensadoun R-J, Roila F; ESMO Guidelines Working Group. Management of oral and gastrointestinal mucositis: ESMO Clinical Practice Guidelines. Ann Oncol. 2011;22(suppl 6):vi78-vi84. 4. Rubenstein EB, Peterson DE, Shubert M, et al. Clinical practice guidelines for the prevention and treatment of cancer therapy-induced oral and gastrointestinal mucositis. Cancer. 2004;100(suppl 9):2026-2046.